Drug manufacturers have been told by pharmacy benefit managers that if they lower prices their drugs could be removed from insurance formularies, Mr. Azar said.
“These are extremely disturbing allegations by Secretary Azar. If they are true, these allegations suggest that PBMs and drug distributors are acting to maintain high list prices in order to maintain high profit margins, potentially raising antitrust concerns,” the senators wrote. “In addition, if PBMs were acting to keep drug prices high, it would directly contradict the public statements that PBMs have made about their actions and their interest in securing lower list prices from drug companies.”
The senators sent letters to executives at CardinalHealth, McKesson, AmerisourceBergen, Medimpact Healthcare Systems, OptumRx, Prime Theraputics, Humana, CVS Health and ExpressScripts. They demanded the companies respond to Mr. Azar’s allegations by July 13.
More articles on leadership and management:
From near bankruptcy to $100M in the bank: How University of Maryland Capital Region Health CEO Neil J. Moore led organizational change
Nashville politicians tied hospital CEO’s contract renewal to continued hospital funding, former hospital board members say
5 lessons for startups from Amazon’s PillPack acquisition
